O'Brien Federica F. 4

What Happened

• Federica F. O'Brien, a director of MacroGenics (MGNX), reported derivative transactions on May 18–19, 2026. She exercised/converted 3,750 option-derived shares on May 18 and the filing also shows a corresponding disposition of 3,750 shares at $0.00. On May 19 she received awards/RSUs totaling 25,750 shares (22,000 + 3,750), all reported with $0.00 per-share value (typical for grants/RSUs).

Key Details

• Transaction dates and reported prices:
  • 2026-05-18: Exercise/conversion (code M) — 3,750 shares acquired (price N/A); same date shows 3,750 shares disposed at $0.00.
  • 2026-05-19: Grant/award (code A) — 22,000 RSUs acquired at $0.00.
  • 2026-05-19: Grant/award (code A) — 3,750 RSUs acquired at $0.00.
• Shares owned after the transactions: not specified in the filing.
• Notable footnotes from the filing:
  • F1: Each RSU represents a contingent right to one share of common stock.
  • F2: Some RSUs vested May 18, 2026 (one day before the company’s 2026 annual meeting).
  • F3: The option (presumably the exercised option) vests monthly in cumulative 1/12th increments, beginning one month from the grant date.
  • F4: Newly granted RSUs vest one year after grant or the day prior to the next annual meeting, if earlier.
• Timeliness: The Form 4 was filed May 20, 2026 for transactions on May 18–19 — the filing appears timely under standard Section 16 deadlines.

Context

• These entries are derivative-related (option exercise and RSU grants/vests), not open-market purchases or sales. The $0.00 per-share values reflect grants/vests rather than cash market trades. The filing does not explain the $0.00 disposition entry for 3,750 shares; the document provides no narrative on settlement method or tax withholding.